Play all audios:
Access through your institution Buy or subscribe Bongartz T _ et al_. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic
review and meta-analysis of rare harmful effects in randomized clinical trials. _JAMA_ 295: 2275–2285 A systematic review and meta-analysis has concluded that patients with rheumatoid
arthritis (RA) treated with the anti-tumor necrosis factor (TNF) antibodies infliximab or adalimumab have an increased risk of serious infections, and a dose-dependent increased risk of
malignancies. There has previously been uncertainty over the extent to which anti-TNF agents are associated with serious infection and malignancy, mainly because of difficulty with the
interpretation of sparse data from trials that were not adequately powered to detect these rare adverse events. This is a preview of subscription content, access via your institution ACCESS
OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on
SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about
institutional subscriptions * Read our FAQs * Contact customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE RA therapy with infliximab and
adalimumab linked with infection and malignancy. _Nat Rev Rheumatol_ 2, 522–523 (2006). https://doi.org/10.1038/ncprheum0279 Download citation * Issue Date: October 2006 * DOI:
https://doi.org/10.1038/ncprheum0279 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not
currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative